- Tytuł:
- Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial
- Autorzy:
- Źródło:
- In The Lancet Oncology October 2022 23(10):1274-1286
Czasopismo naukowe